We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Key Takeaways
Jakafi sales and stronger royalties from Novartis are expected to have driven top-line growth for INCY.
Opzelura sales are likely to have risen on increased patient starts as well as strong EU uptake.
Niktimvo launch and Monjuvi's label expansion may have supported incremental revenue contributions.
We expect Incyte Corporation (INCY - Free Report) to surpass expectations when it reports second-quarter 2025 earnings on July 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.15 billion, while the same for earnings is pinned at $1.40 per share.
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence INCY's Q2 Results
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have continued on the back of strong Jakafi sales, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]). However, competition from other drugs may have limited the sales growth potential to some extent.
The Zacks Consensus Estimate for Jakafi's second-quarter sales is pegged at $744 million.
Incyte also earns product royalty revenues from Novartis (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets.
While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter on higher Jakavi sales.
Novartis reported solid performance of Jakavi in the second quarter of 2025, with sales of the drug witnessing an 8% increase on a constant currency basis. Hence, royalties from the same are likely to have been higher.
Year to date, shares of Incyte have risen 2.4% against the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. NVS has exclusive worldwide development and commercialization rights to Tabrecta.
In the to-be-reported quarter, INCY expects growth in Opzelura sales to be driven by continued growth in new patient starts and refills in the United States and increased contribution from the EU.
The Zacks Consensus Estimate for Opzelura’s second-quarter sales is pegged at $149 million.
While Jakafi’s sales and royalties are the key catalysts for Incyte’s revenue growth, sales of other drugs like Minjuvi, Pemazyre and Iclusig and Olumiant’s royalties from Eli Lilly are also likely to have contributed to Incyte’s top line. In 2024, the company entered into an asset purchase agreement with MorphoSys AG. This gave Incyte exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the United States (as Monjuvi) and outside the country (as Minjuvi).
In May, the FDA approved Monjuvi for a new cancer indication. The regulatory body approved Monjuvi in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for the treatment of adult patients with relapsed or refractory follicular lymphoma, a type of slow-growing blood cancer. The label expansion of the drug is likely to have boosted sales of the drug.
The Zacks Consensus Estimate for Iclusig, Minjuvi and Pemazyre’s second-quarter sales is pegged at $28.99 million, $34.25 million and $20.24 million, respectively. Incremental sales from Zynyz, too, are expected to have boosted Incyte’s revenues in the to-be-reported quarter.
Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of GVHD after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo. The drug is Incyte’s second approved treatment for chronic GvHD (third-line) and was launched in the United States during the first quarter of 2025. Niktimvo recorded $13.6 million in sales in the last reported quarter, following its launch.
Investors will be keen to get further updates on the ongoing launch activities for Niktimvo and its sales performance during the upcoming earnings announcement.
Per management, 2025 is poised to be a transformational year for INCY, with several potential near-term launches and several clinical milestones expected.Higher research and development expenses, as well as increased selling and general and administrative costs, are likely to have escalated operating expenses in the second quarter.
INCY's Earnings Surprise History
Incyte has a disappointing history of earnings surprises. The company beat on earnings in one of the trailing four quarters, while missing the same on the remaining three occasions, delivering an average negative surprise of 82.37%. In the last reported quarter, INCY posted an earnings surprise of 14.85%.
Our proven model predicts an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is exactly the case here, as you will see below.
INCY’s Earnings ESP: Incyte’s Earnings ESP is +1.43% as the Most Accurate Estimate currently stands at $1.42, higher than the Zacks Consensus Estimate, which is pegged at $1.40. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Here are a few stocks worth considering from the healthcare space, as our model shows that these also have the right combination of elements to beat on earnings this reporting cycle.
Akero Therapeutics (AKRO - Free Report) has an Earnings ESP of +0.53% and a Zacks Rank #1 at present.
AKRO stock has surged 86.3% year to date. Akero beat on earnings in three of the last four quarters and missed in one, delivering an average surprise of 48.90%.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have lost 13.9% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Key Takeaways
We expect Incyte Corporation (INCY - Free Report) to surpass expectations when it reports second-quarter 2025 earnings on July 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.15 billion, while the same for earnings is pinned at $1.40 per share.
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence INCY's Q2 Results
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have continued on the back of strong Jakafi sales, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]). However, competition from other drugs may have limited the sales growth potential to some extent.
The Zacks Consensus Estimate for Jakafi's second-quarter sales is pegged at $744 million.
Incyte also earns product royalty revenues from Novartis (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets.
While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter on higher Jakavi sales.
Novartis reported solid performance of Jakavi in the second quarter of 2025, with sales of the drug witnessing an 8% increase on a constant currency basis. Hence, royalties from the same are likely to have been higher.
Year to date, shares of Incyte have risen 2.4% against the industry’s decline of 0.5%.
Image Source: Zacks Investment Research
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. NVS has exclusive worldwide development and commercialization rights to Tabrecta.
In the to-be-reported quarter, INCY expects growth in Opzelura sales to be driven by continued growth in new patient starts and refills in the United States and increased contribution from the EU.
The Zacks Consensus Estimate for Opzelura’s second-quarter sales is pegged at $149 million.
While Jakafi’s sales and royalties are the key catalysts for Incyte’s revenue growth, sales of other drugs like Minjuvi, Pemazyre and Iclusig and Olumiant’s royalties from Eli Lilly are also likely to have contributed to Incyte’s top line. In 2024, the company entered into an asset purchase agreement with MorphoSys AG. This gave Incyte exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the United States (as Monjuvi) and outside the country (as Minjuvi).
In May, the FDA approved Monjuvi for a new cancer indication. The regulatory body approved Monjuvi in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for the treatment of adult patients with relapsed or refractory follicular lymphoma, a type of slow-growing blood cancer. The label expansion of the drug is likely to have boosted sales of the drug.
The Zacks Consensus Estimate for Iclusig, Minjuvi and Pemazyre’s second-quarter sales is pegged at $28.99 million, $34.25 million and $20.24 million, respectively. Incremental sales from Zynyz, too, are expected to have boosted Incyte’s revenues in the to-be-reported quarter.
Incyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of GVHD after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo. The drug is Incyte’s second approved treatment for chronic GvHD (third-line) and was launched in the United States during the first quarter of 2025. Niktimvo recorded $13.6 million in sales in the last reported quarter, following its launch.
Investors will be keen to get further updates on the ongoing launch activities for Niktimvo and its sales performance during the upcoming earnings announcement.
Per management, 2025 is poised to be a transformational year for INCY, with several potential near-term launches and several clinical milestones expected.Higher research and development expenses, as well as increased selling and general and administrative costs, are likely to have escalated operating expenses in the second quarter.
INCY's Earnings Surprise History
Incyte has a disappointing history of earnings surprises. The company beat on earnings in one of the trailing four quarters, while missing the same on the remaining three occasions, delivering an average negative surprise of 82.37%. In the last reported quarter, INCY posted an earnings surprise of 14.85%.
Incyte Corporation Price and EPS Surprise
Incyte Corporation price-eps-surprise | Incyte Corporation Quote
Earnings Whispers for INCY Stock
Our proven model predicts an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is exactly the case here, as you will see below.
INCY’s Earnings ESP: Incyte’s Earnings ESP is +1.43% as the Most Accurate Estimate currently stands at $1.42, higher than the Zacks Consensus Estimate, which is pegged at $1.40. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
INCY’s Zacks Rank: INCY has a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks With the Favorable Combination
Here are a few stocks worth considering from the healthcare space, as our model shows that these also have the right combination of elements to beat on earnings this reporting cycle.
Akero Therapeutics (AKRO - Free Report) has an Earnings ESP of +0.53% and a Zacks Rank #1 at present.
AKRO stock has surged 86.3% year to date. Akero beat on earnings in three of the last four quarters and missed in one, delivering an average surprise of 48.90%.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have lost 13.9% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close.